Prostate cancer (PCa) is the most common neoplasm in men and a major cause of cancer-associated deaths. Androgen deprivation therapy is the initial standard treatment for patients with PCa. However, the vast majority of patients will experience disease progression, with the condition then being regarded as castration-resistant prostate cancer. Cytotoxic chemotherapy was relatively ineffective in these patients until the development of taxanes. Recent studies have expanded the treatment options in these patients, according to the presence of symptoms, location of metastatic disease and the expression of some biomarkers.

Born in Jalisco, Mexico. Graduated from the degree in General Medicine from the University of Guadalajara, Mexico. He started his medial residency in Internal Medicine at the Regional Hospital “Manuel Cardenas de la Vega” ISSSTE, Culiacán, Sinaloa. Subsequently, he was referred to sub-speciality in Medical Oncology at the National Medical Center “20 de Noviembre”, ISSSTE, Mexico City. He has worked in public institutions and currently works in the private sector, ONCOLIFE Mexico.